Advances in the Anticancer Value of the Ursolic Acid Through Nanodelivery

2019 ◽  
Vol 25 (37) ◽  
pp. 4866-4875 ◽  
Author(s):  
Azadeh Manayi ◽  
Marjan Nikan ◽  
Navid Nobakht-Haghighi ◽  
Mohammad Abdollahi
Keyword(s):  
Drug Delivery ◽  
Ursolic Acid ◽  
Drug Delivery Systems ◽  
Delivery Systems ◽  
The Body ◽  
Pentacyclic Triterpenoid ◽  
Specific Distribution ◽  
Nano Drug Delivery ◽  
Recent Developments ◽  
Therapeutic Development

Ursolic acid, a natural pentacyclic triterpenoid is commonly found in plants and foods with promising biological and pharmacological activities. The compound has been under the attention of researchers due to its considerable anticancer effects through suppression of differentiation, angiogenesis, invasion, and metastasis of tumor cells via different pathways with low toxicity. Bioavailability of ursolic acid is poor due to poor solubility of the compound in water. Low bioavailability and short plasma half-life of ursolic acid along with non-specific distribution in the body are considered as impediments in the therapeutic development of the compound. Nano-drug delivery systems may improve the pharmacokinetic, bioavailability, and therapeutic activity of some medicines. The present review has focused on recent developments regarding nano-drug delivery systems of ursolic acid in cancer therapy.

scholarly journals Evolution from small molecule to nano-drug delivery systems: An emerging approach for cancer therapy of ursolic acid

2020 ◽  
Vol 15 (6) ◽  
pp. 685-700 ◽  
Author(s):  
Jingwei Shao ◽  
Yifan Fang ◽  
Ruirui Zhao ◽  
Fangmin Chen ◽  
Mingyue Yang ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Cancer Therapy ◽  
Ursolic Acid ◽  
Small Molecule ◽  
Drug Delivery Systems ◽  
Delivery Systems ◽  
Nano Drug Delivery

scholarly journals Thrombolytic Agents: Nanocarriers in Targeted Release

Molecules ◽  
2021 ◽  
Vol 26 (22) ◽  
pp. 6776
Author(s):  
Minghua Shen ◽  
Yujiao Wang ◽  
Fan Hu ◽  
Linwen Lv ◽  
Kui Chen ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Drug Delivery Systems ◽  
Vascular System ◽  
Blood Clot ◽  
Delivery Systems ◽  
The Body ◽  
High Morbidity ◽  
Nano Drug Delivery ◽  
Underlying Pathology ◽  
Targeted Release

A thrombus, known as a blood clot, may form within the vascular system of the body and impede blood flow. Thrombosis is the most common underlying pathology of cardiovascular diseases, contributing to high morbidity and mortality. However, the main thrombolytic drugs (urokinase, streptokinase, etc.) have shortcomings, including a short half-life, serious side effects and a lack of targeting, that limit their clinical application. The use of nano-drug delivery systems is expected to address these problems and a variety of approaches, including biological and physical responsive systems, have been explored. In this report, recent advances in the development of targeted nano-drug delivery systems are thoroughly reviewed.

Recent Advances of Mesoporous Silica Based Multifunctional Nano Drug Delivery Systems

2013 ◽  
Vol 40 (10) ◽  
pp. 1014
Author(s):  
Xiao-Hong HAO ◽  
Cui-Miao ZHANG ◽  
Xiao-Long LIU ◽  
Xing-Jie LIANG ◽  
Guang JIA ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Mesoporous Silica ◽  
Drug Delivery Systems ◽  
Delivery Systems ◽  
Recent Advances ◽  
Nano Drug Delivery

Biocompatible Nanovesicular Drug Delivery Systems with Targeting Potential for Autoimmune Diseases

2020 ◽  
Vol 26 (42) ◽  
pp. 5488-5502 ◽  
Author(s):  
Yub Raj Neupane ◽  
Asiya Mahtab ◽  
Lubna Siddiqui ◽  
Archu Singh ◽  
Namrata Gautam ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Autoimmune Diseases ◽  
Lupus Erythematosus ◽  
Drug Delivery Systems ◽  
Drug Carriers ◽  
Immunological Tolerance ◽  
Delivery Systems ◽  
The Body ◽  
Autoimmune Response ◽  
Treatment Modalities

Autoimmune diseases are collectively addressed as chronic conditions initiated by the loss of one’s immunological tolerance, where the body treats its own cells as foreigners or self-antigens. These hay-wired antibodies or immunologically capable cells lead to a variety of disorders like rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosus, multiple sclerosis and recently included neurodegenerative diseases like Alzheimer’s, Parkinsonism and testicular cancer triggered T-cells induced autoimmune response in testes and brain. Conventional treatments for autoimmune diseases possess several downsides due to unfavourable pharmacokinetic behaviour of drug, reflected by low bioavailability, rapid clearance, offsite toxicity, restricted targeting ability and poor therapeutic outcomes. Novel nanovesicular drug delivery systems including liposomes, niosomes, proniosomes, ethosomes, transferosomes, pharmacosomes, ufasomes and biologically originated exosomes have proved to possess alluring prospects in supporting the combat against autoimmune diseases. These nanovesicles have revitalized available treatment modalities as they are biocompatible, biodegradable, less immunogenic and capable of carrying high drug payloads to deliver both hydrophilic as well as lipophilic drugs to specific sites via passive or active targeting. Due to their unique surface chemistry, they can be decorated with physiological or synthetic ligands to target specific receptors overexpressed in different autoimmune diseases and can even cross the blood-brain barrier. This review presents exhaustive yet concise information on the potential of various nanovesicular systems as drug carriers in improving the overall therapeutic efficiency of the dosage regimen for various autoimmune diseases. The role of endogenous exosomes as biomarkers in the diagnosis and prognosis of autoimmune diseases along with monitoring progress of treatment will also be highlighted.

Improving the Efficacy of Anticancer Drugs via Encapsulation and Acoustic Release

2018 ◽  
Vol 18 (10) ◽  
pp. 857-880 ◽  
Author(s):  
Salma E. Ahmed ◽  
Nahid Awad ◽  
Vinod Paul ◽  
Hesham G. Moussa ◽  
Ghaleb A. Husseini
Keyword(s):  
Drug Delivery ◽  
Drug Release ◽  
Drug Delivery Systems ◽  
Delivery Systems ◽  
Special Focus ◽  
Nano Drug Delivery ◽  
Medical Researchers ◽  
History Of ◽  
Overall Performance ◽  
Enhanced Stability

Conventional chemotherapeutics lack the specificity and controllability, thus may poison healthy cells while attempting to kill cancerous ones. Newly developed nano-drug delivery systems have shown promise in delivering anti-tumor agents with enhanced stability, durability and overall performance; especially when used along with targeting and triggering techniques. This work traces back the history of chemotherapy, addressing the main challenges that have encouraged the medical researchers to seek a sanctuary in nanotechnological-based drug delivery systems that are grafted with appropriate targeting techniques and drug release mechanisms. A special focus will be directed to acoustically triggered liposomes encapsulating doxorubicin.

Nanoscale Drug Delivery Systems for Glaucoma: Experimental and In Silico Advances

2020 ◽  
Vol 20 ◽  
Author(s):  
Smriti Sharma ◽  
Vinayak Bhatia
Keyword(s):  
Drug Delivery ◽  
In Silico ◽  
Drug Delivery Systems ◽  
Delivery Systems ◽  
Ocular Drug Delivery ◽  
The Body ◽  
Single Wall Carbon Nanotubes ◽  
Blood Retinal Barrier ◽  
Novel Drugs ◽  
Blood Aqueous Barrier

: In this review nanoscale based drug delivery systems particularly in relevance to the antiglaucoma drugs have been discussed. In addition to that, the latest computational/in silico advances in this field are examined in brief. Using nanoscale materials for drug delivery, is an ideal option to target tumours and drug can be released at areas of the body where traditional drugs may fail to act. Nanoparticles, polymeric nanomaterials, single-wall carbon nanotubes (SWCNTs), quantum dots (QDs), liposomes and graphene are the most important nanomaterials used for drug delivery. Ocular drug delivery is one of the most common and difficult tasks faced by pharmaceutical scientists because of many challenges like circumventing the blood–retinal barrier, corneal epithelium and the blood–aqueous barrier. Authors found compelling empirical evidence of scientists relying on in-silico approaches to develop novel drugs and drug delivery systems for treating glaucoma. This review in nanoscale drug delivery systems will help us in understand the existing queries and evidence gaps and will pave way for effective design of novel ocular drug delivery systems

Current HPLC Methods for Assay of Nano Drug Delivery Systems

2017 ◽  
Vol 17 (13) ◽  
pp. 1588-1594 ◽  
Author(s):  
Serife Evrim Kepekci Tekkeli ◽  
Mustafa Volkan Kiziltas
Keyword(s):  
Drug Delivery ◽  
Drug Delivery Systems ◽  
Delivery Systems ◽  
Nano Drug Delivery

Nanostructured Ketorolac-Tromethamine/MCF: Synthesis, Characterization and Application in Drug Release System

2018 ◽  
Vol 14 (5) ◽  
pp. 432-439 ◽  
Author(s):  
Juliana M. Juarez ◽  
Jorgelina Cussa ◽  
Marcos B. Gomez Costa ◽  
Oscar A. Anunziata
Keyword(s):  
Drug Delivery ◽  
Drug Release ◽  
Therapeutic Efficacy ◽  
Drug Delivery Systems ◽  
Controlled Drug Release ◽  
Delivery Systems ◽  
The Body ◽  
Fickian Diffusion ◽  
Ketorolac Tromethamine

Background: Controlled drug delivery systems can maintain the concentration of drugs in the exact sites of the body within the optimum range and below the toxicity threshold, improving therapeutic efficacy and reducing toxicity. Mesostructured Cellular Foam (MCF) material is a new promising host for drug delivery systems due to high biocompatibility, in vivo biodegradability and low toxicity. Methods: Ketorolac-Tromethamine/MCF composite was synthesized. The material synthesis and loading of ketorolac-tromethamine into MCF pores were successful as shown by XRD, FTIR, TGA, TEM and textural analyses. Results: We obtained promising results for controlled drug release using the novel MCF material. The application of these materials in KETO release is innovative, achieving an initial high release rate and then maintaining a constant rate at high times. This allows keeping drug concentration within the range of therapeutic efficacy, being highly applicable for the treatment of diseases that need a rapid response. The release of KETO/MCF was compared with other containers of KETO (KETO/SBA-15) and commercial tablets. Conclusion: The best model to fit experimental data was Ritger-Peppas equation. Other models used in this work could not properly explain the controlled drug release of this material. The predominant release of KETO from MCF was non-Fickian diffusion.

Sign in / Sign up

Export Citation Format

Share Document